Endogen
This article was originally published in The Gray Sheet
Executive Summary
Begins trading on the NASDAQ market following the acquisition of Diagnostics Holding Corporation's outstanding stock in exchange for approximately 1.2 mil. shares of Endogen common stock. As a result of the transaction, the manufacturer of research products and immunoassay test kits adds to its cash reserves $3.1 mil. that DHC possessed at the time of the transaction. Endogen says in a March 19 release that the DHC purchase allows the firm "to accelerate...internal growth and to pursue possible acquisitions of companies or product lines in the research products and niche diagnostics fields." DHC was formed as part of a reorganization involving Recordati and Recordati's majority- owned subsidiary, Leeco Diagnostics ("The Gray Sheet" Dec. 21, p. 16). As a result of the merger with Endogen, Leeco shareholders other than Recordati own approximately 47% of outstanding Endogen common shares, which total approximately 2.6 mil.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.